These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

398 related articles for article (PubMed ID: 26850485)

  • 1. Genetic/Familial High-Risk Assessment: Breast and Ovarian, Version 2.2015.
    Daly MB; Pilarski R; Axilbund JE; Berry M; Buys SS; Crawford B; Farmer M; Friedman S; Garber JE; Khan S; Klein C; Kohlmann W; Kurian A; Litton JK; Madlensky L; Marcom PK; Merajver SD; Offit K; Pal T; Rana H; Reiser G; Robson ME; Shannon KM; Swisher E; Voian NC; Weitzel JN; Whelan A; Wick MJ; Wiesner GL; Dwyer M; Kumar R; Darlow S
    J Natl Compr Canc Netw; 2016 Feb; 14(2):153-62. PubMed ID: 26850485
    [TBL] [Abstract][Full Text] [Related]  

  • 2. NCCN Guidelines Insights: Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 1.2020.
    Daly MB; Pilarski R; Yurgelun MB; Berry MP; Buys SS; Dickson P; Domchek SM; Elkhanany A; Friedman S; Garber JE; Goggins M; Hutton ML; Khan S; Klein C; Kohlmann W; Kurian AW; Laronga C; Litton JK; Mak JS; Menendez CS; Merajver SD; Norquist BS; Offit K; Pal T; Pederson HJ; Reiser G; Shannon KM; Visvanathan K; Weitzel JN; Wick MJ; Wisinski KB; Dwyer MA; Darlow SD
    J Natl Compr Canc Netw; 2020 Apr; 18(4):380-391. PubMed ID: 32259785
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical Actionability of Multigene Panel Testing for Hereditary Breast and Ovarian Cancer Risk Assessment.
    Desmond A; Kurian AW; Gabree M; Mills MA; Anderson MJ; Kobayashi Y; Horick N; Yang S; Shannon KM; Tung N; Ford JM; Lincoln SE; Ellisen LW
    JAMA Oncol; 2015 Oct; 1(7):943-51. PubMed ID: 26270727
    [TBL] [Abstract][Full Text] [Related]  

  • 4. NCCN Guidelines Insights: Genetic/Familial High-Risk Assessment: Breast and Ovarian, Version 2.2017.
    Daly MB; Pilarski R; Berry M; Buys SS; Farmer M; Friedman S; Garber JE; Kauff ND; Khan S; Klein C; Kohlmann W; Kurian A; Litton JK; Madlensky L; Merajver SD; Offit K; Pal T; Reiser G; Shannon KM; Swisher E; Vinayak S; Voian NC; Weitzel JN; Wick MJ; Wiesner GL; Dwyer M; Darlow S
    J Natl Compr Canc Netw; 2017 Jan; 15(1):9-20. PubMed ID: 28040716
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ACOG Practice Bulletin No. 103: Hereditary breast and ovarian cancer syndrome.
    Obstet Gynecol; 2009 Apr; 113(4):957-966. PubMed ID: 19305347
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hereditary breast-ovarian cancer: clinical findings and medical management.
    Marshall M; Solomon S
    Plast Surg Nurs; 2007; 27(3):124-7. PubMed ID: 17901820
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk estimation as a decision-making tool for genetic analysis of the breast cancer susceptibility genes. EC Demonstration Project on Familial Breast Cancer.
    Chang-Claude J; Becher H; Caligo M; Eccles D; Evans G; Haites N; Hodgson S; Møller P; Weber BH; Stoppa-Lyonnet D
    Dis Markers; 1999 Oct; 15(1-3):53-65. PubMed ID: 10595253
    [TBL] [Abstract][Full Text] [Related]  

  • 8. NCCN Guidelines® Insights: Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 2.2024.
    Daly MB; Pal T; Maxwell KN; Churpek J; Kohlmann W; AlHilli Z; Arun B; Buys SS; Cheng H; Domchek SM; Friedman S; Giri V; Goggins M; Hagemann A; Hendrix A; Hutton ML; Karlan BY; Kassem N; Khan S; Khoury K; Kurian AW; Laronga C; Mak JS; Mansour J; McDonnell K; Menendez CS; Merajver SD; Norquist BS; Offit K; Rash D; Reiser G; Senter-Jamieson L; Shannon KM; Visvanathan K; Welborn J; Wick MJ; Wood M; Yurgelun MB; Dwyer MA; Darlow SD
    J Natl Compr Canc Netw; 2023 Oct; 21(10):1000-1010. PubMed ID: 37856201
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Patients Tested at a Laboratory for Hereditary Cancer Syndromes Show an Overlap for Multiple Syndromes in Their Personal and Familial Cancer Histories.
    Saam J; Arnell C; Theisen A; Moyes K; Marino I; Roundy KM; Wenstrup RJ
    Oncology; 2015; 89(5):288-93. PubMed ID: 26315041
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of National Comprehensive Cancer Network guideline-based Tool for Risk Assessment for breast and ovarian Cancer (N-TRAC): A patient-reported survey for genetic high-risk assessment for breast and ovarian cancers in women.
    Ozanne EM; Howe R; Mallinson D; Esserman L; Van't Veer LJ; Kaplan CP
    J Genet Couns; 2019 Jun; 28(3):507-515. PubMed ID: 30663827
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genetic counseling for breast cancer.
    Clark S; Iglehart JD
    Adv Surg; 1999; 33():199-215. PubMed ID: 10572568
    [No Abstract]   [Full Text] [Related]  

  • 12. Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology.
    Daly MB; Pal T; Berry MP; Buys SS; Dickson P; Domchek SM; Elkhanany A; Friedman S; Goggins M; Hutton ML; ; Karlan BY; Khan S; Klein C; Kohlmann W; ; Kurian AW; Laronga C; Litton JK; Mak JS; ; Menendez CS; Merajver SD; Norquist BS; Offit K; Pederson HJ; Reiser G; ; Senter-Jamieson L; ; Shannon KM; Shatsky R; Visvanathan K; Weitzel JN; Wick MJ; Wisinski KB; Yurgelun MB; Darlow SD; Dwyer MA
    J Natl Compr Canc Netw; 2021 Jan; 19(1):77-102. PubMed ID: 33406487
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer: US Preventive Services Task Force Recommendation Statement.
    ; Owens DK; Davidson KW; Krist AH; Barry MJ; Cabana M; Caughey AB; Doubeni CA; Epling JW; Kubik M; Landefeld CS; Mangione CM; Pbert L; Silverstein M; Simon MA; Tseng CW; Wong JB
    JAMA; 2019 Aug; 322(7):652-665. PubMed ID: 31429903
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cancer risk assessment and the genetic counseling process: using hereditary breast and ovarian cancer as an example.
    Prucka SK; McIlvried DE; Korf BR
    Med Princ Pract; 2008; 17(3):173-89. PubMed ID: 18408385
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multigene Testing for Hereditary Cancer: When, Why, and How.
    Offit K
    J Natl Compr Canc Netw; 2017 May; 15(5S):741-743. PubMed ID: 28515260
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Time to incorporate germline multigene panel testing into breast and ovarian cancer patient care.
    Graffeo R; Livraghi L; Pagani O; Goldhirsch A; Partridge AH; Garber JE
    Breast Cancer Res Treat; 2016 Dec; 160(3):393-410. PubMed ID: 27734215
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Hereditary breast and ovarian cancer - indications for genetic testing, counseling and options for mutation carriers].
    Bürki N
    Ther Umsch; 2010 Jul; 67(7):359-66. PubMed ID: 20577964
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hereditary breast and ovarian cancer and other hereditary syndromes: using technology to identify carriers.
    Drohan B; Roche CA; Cusack JC; Hughes KS
    Ann Surg Oncol; 2012 Jun; 19(6):1732-7. PubMed ID: 22427173
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of Panel Gene Testing for Hereditary Breast and Ovarian Cancer on Patients.
    Lumish HS; Steinfeld H; Koval C; Russo D; Levinson E; Wynn J; Duong J; Chung WK
    J Genet Couns; 2017 Oct; 26(5):1116-1129. PubMed ID: 28357778
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hereditary breast and ovarian cancer syndrome: should we test adolescents?
    Seeber B; Driscoll DA
    J Pediatr Adolesc Gynecol; 2004 Jun; 17(3):161-7. PubMed ID: 15125901
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 20.